Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parmax PharmaBOM:540359 43 EV-to-EBIT is -63.57 as of Sep. 21, 2026. GuruFocus rates BOM:540359 with a GF Score™ of 43/100 and a GF Value™ of ₹22.99 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 682 Drug Manufacturers companies, Parmax Pharma ranks worse than 146627.42% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Parmax Pharma's Enterprise Value for the quarter that ended in Jun. 2026 was ₹292.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Parmax Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-16.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parmax Pharma EV-to-EBIT Related Terms
Parmax Pharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Parmax Pharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parmax Pharma EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Parmax Pharma's EV-to-EBIT falls into.
Parmax Pharma's current Enterprise Value is ₹1,043.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Parmax Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-16.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parmax Pharma (BOM:540359) has a EV-to-EBIT of -63.57 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Parmax Pharma and its competitors. According to the industry distribution chart, Parmax Pharma ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Parmax Pharma's EV-to-EBIT too high?
Parmax Pharma's current EV-to-EBIT is -63.57. Based on the distribution chart, Parmax Pharma ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Parmax Pharma has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Parmax Pharma ranks #999999 out of 682 companies for EV-to-EBIT. This places Parmax Pharma in the lower half of its industry. The industry median EV-to-EBIT is 16.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.08, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Parmax Pharma and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parmax Pharma's current EV-to-EBIT is -63.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹22.99, compared to a current price of ₹135.05 — trading 487.4% above its estimated fair value. The current EV-to-EBIT is -63.57. Parmax Pharma's overall GF Score™ is 43/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current EV-to-EBIT is -63.57 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parmax Pharma (BOM:540359) Overvalued in 2026?
Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued.
The current stock price of ₹135.05 is trading 487.4% above its estimated GF Value™ of ₹22.99.
GuruFocus considers Parmax Pharma to be Significantly Overvalued.
Key valuation signals for BOM:540359:
EV-to-EBIT: -63.57
GF Value™: ₹22.99 vs. price of ₹135.05 (487.4% above fair value)
No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540359 has been successfully added to your 
